SCHEMBL733030

SCHEMBL733030

COC(=O)c1ccc(O)c(C)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.55
CA2 P00918 6/20 0.55
CA9 Q16790 6/20 0.55
CA12 O43570 5/20 0.55
CA7 P43166 5/20 0.55
CA14 Q9ULX7 5/20 0.55
PDK2 Q15119 1/20 0.55
PDK4 Q16654 1/20 0.55
LMNA P02545 1/20 0.53
TSHR P16473 1/20 0.53
GAA P10253 3/20 0.52
MYC P01106 1/20 0.49
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
XDH P47989 1/20 0.47
PTGS2 P35354 1/20 0.45
GLA P06280 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422644 0.89 CA12 (0.54) CA1CA2CA9CA12CA7
SCHEMBL3761829 0.86 CA12 (0.53) CA1CA2CA9CA12CA7
SCHEMBL2590792 0.86 CA12 (0.53) CA1CA2CA9CA12CA7
SCHEMBL30466430 0.86 CA12 (0.53) CA1CA2CA9CA12CA7
SCHEMBL12553221 0.84 CA12 (0.59) CA1CA2CA9CA12CA7
SCHEMBL2456583 0.83 MEN1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL24820610 0.82 CA12 (0.50) CA1CA2CA9CA12CA7
SCHEMBL30966098 0.82 CA1 (0.50) CA1CA2CA9CA12CA7
SCHEMBL25475896 0.82 CA1 (0.50) CA1CA2CA9CA12CA7
SCHEMBL21438533 0.82 CA1 (0.50) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113748021-B Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2024-07-05 CN claimed
US-20260138990-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS INC (US) 2026-05-21 US disclosed
EP-4702026-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF Aeovian Pharmaceuticals, Inc. (US) 2026-03-04 EP disclosed
US-12421452-B2 Method for producing liquid-crystal polyester processed product HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2025-09-23 US disclosed
WO-2024226685-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. (US) 2024-10-31 WO disclosed
CN-113748021-B Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2024-07-05 CN disclosed
US-20240084196-A1 METHOD FOR PRODUCING LIQUID-CRYSTAL POLYESTER PROCESSED PRODUCT HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2024-03-14 US disclosed
US-11884864-B2 Method for producing liquid-crystal polyester processed product HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2024-01-30 US disclosed
CN-117257779-A Phloroglucinol compound injection 康普药业股份有限公司 2023-12-22 CN disclosed
US-20220204853-A1 METHOD FOR PRODUCING LIQUID-CRYSTAL POLYESTER PROCESSED PRODUCT HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2022-06-30 US disclosed
US-20100316555-A1 PROCESS FOR PRODUCING CARBON Sumitomt Chemical Company, Limited (JP) 2010-12-16 US disclosed
US-20100029631-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-04 US disclosed
US-7601712-B2 Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists ONO PHARMACEUTICAL CO., LTD. (JP) 2009-10-13 US disclosed
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-04 US disclosed
EP-1666473-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed
CN-1257886-C Dehydroamino acids compounds HOFFMANN LA ROCHE (CH) 2006-05-31 CN disclosed
EP-1317241-A2 SHAMPOO COMPOSITIONS WITH CATIONIC POLYMERS THE PROCTER & GAMBLE COMPANY (US) 2003-06-11 EP disclosed
CN-1398252-A dehydroamino acid compounds HOFFMANN LA ROCHE (CH) 2003-02-19 CN disclosed
WO-2002022091-A2 SHAMPOO COMPOSITIONS WITH CATIONIC POLYMERS PROCTER & GAMBLE COMPANY (US) 2002-03-21 WO disclosed
US-20020012646-A1 Shampoo compositions with cationic polymers PROCTER & GAMBLE COMPANY, THE 2002-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138990-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF CD38, BCL9, BCL6B CA1 789/4885CA2 187/4885CA9 73/4885
US-20100029631-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT GPR17, CYSLTR1, KIT CA1 542/4885CA2 374/4885CA9 1505/4885
US-20020012646-A1 Shampoo compositions with cationic polymers S100P, PSAP, PHOSPHO1 CA1 1620/4885CA2 818/4885CA9 3022/4885
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient GPR17, CYSLTR1, KIT CA1 542/4885CA2 374/4885CA9 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.